The British drugmaker throws in the towel on a study that could have positioned Epanova to compete against Amarin's Vascepa.
News & Analysis: AstraZeneca
The FDA was in a big hurry to make these new therapies available for patients who need them.
It's been 16 years since we've seen influenza-related illnesses ramp up this quickly in the U.S.
There's a new treatment option on the way for breast cancer patients who have exhausted all their other options.
The stock price is soaring. Are investors getting ahead of themselves by speculating on a potential acquisition?
These big drugmakers' CEOs have delivered strong total returns and enjoy widespread employee approval.
FibroGen reported highly anticipated clinical data on Friday for its lead drug roxadustat in chronic kidney disease.
These three healthcare companies have a lot of good things going for them.
AstraZeneca's stock has crushed its closest peers over the past three years. Can it keep heading higher?
It’s rejected a pair of drugs in the last six months.